OBJECTIVE: To determine whether there are specific cytochrome P450 (CYP2) alleles that increase susceptibility to scleroderma in individuals who have been exposed to organic solvents. METHODS: CYP alleles at 2 loci, 2E1 and 2C19, were compared in 7 patients who had developed scleroderma after exposure to solvents versus 71 patients with scleroderma without solvent exposure ("sporadic" disease) and 106 population controls. RESULTS: The 2E1*3 allele was found in 2 of the 7 patients who had been exposed to organic solvents, with a greater frequency than occurred in either the disease controls or the population controls (odds ratio [95% confidence interval] 9.1 [1.5-59.1] and 10.2 [1.8-62.2], respectively). All 7 patients with solvent exposure carried the 2C19EM genotype, compared with 89% of patients with sporadic scleroderma. CONCLUSION: Our results suggest that alleles at CYP loci may be involved in increasing susceptibility to scleroderma among subjects who have been exposed to organic solvents.
OBJECTIVE: To determine whether there are specific cytochrome P450 (CYP2) alleles that increase susceptibility to scleroderma in individuals who have been exposed to organic solvents. METHODS:CYP alleles at 2 loci, 2E1 and 2C19, were compared in 7 patients who had developed scleroderma after exposure to solvents versus 71 patients with scleroderma without solvent exposure ("sporadic" disease) and 106 population controls. RESULTS: The 2E1*3 allele was found in 2 of the 7 patients who had been exposed to organic solvents, with a greater frequency than occurred in either the disease controls or the population controls (odds ratio [95% confidence interval] 9.1 [1.5-59.1] and 10.2 [1.8-62.2], respectively). All 7 patients with solvent exposure carried the 2C19EM genotype, compared with 89% of patients with sporadic scleroderma. CONCLUSION: Our results suggest that alleles at CYP loci may be involved in increasing susceptibility to scleroderma among subjects who have been exposed to organic solvents.
Authors: K Skretkowicz; J Skretkowicz; B Gawrońska-Szklarz; W Górnik; M Rychlik-Sych; A Sysa-Jedrzejowska Journal: Eur J Clin Pharmacol Date: 2004-11-24 Impact factor: 2.953
Authors: Ivan Rusyn; Weihsueh A Chiu; Lawrence H Lash; Hans Kromhout; Johnni Hansen; Kathryn Z Guyton Journal: Pharmacol Ther Date: 2013-08-23 Impact factor: 12.310
Authors: Sara A Miller-Archie; Peter M Izmirly; Jessica R Berman; Jennifer Brite; Deborah J Walker; Renato C Dasilva; Lysa J Petrsoric; James E Cone Journal: Arthritis Rheumatol Date: 2020-04-01 Impact factor: 10.995
Authors: Soe Mar; Shannon Liang; Michael Waltz; T Charles Casper; Manu Goyal; Benjamin Greenberg; Bianca Weinstock-Guttman; Moses Rodriguez; Gregory Aaen; Anita Belman; Lisa F Barcellos; John Rose; Mark Gorman; Leslie Benson; Meghan Candee; Tanjua Chitnis; Yolanda Harris; Ilana Kahn; Shelly Roalsted; Janace Hart; Timothy Lotze; Manikum Moodley; Jayne Ness; Mary Rensel; Jennifer Rubin; Teri Schreiner; Jan-Mendelt Tillema; Amy Waldman; Lauren Krupp; Jennifer S Graves; Emmanuelle Waubant Journal: Ann Clin Transl Neurol Date: 2018-10-09 Impact factor: 4.511